Skip to main content
. 2013 Winter;18(1):e40–e43.

TABLE 1.

Baseline characteristics of the two groups with chronic pulmonary heart disease

Variable Group
P
Treatment (n=33) Untreated control (n=35)
Age, mean ± SD 66.2±7.4 64.9±8.2 NS
Female sex 13 (39.4) 12 (34.2) NS
Heart rate, beats/min, mean ± SD 110.3±9.6 107.7±8.2 NS
NYHA class
  I 0 (0) 0 (0) NS
  II 15 (45.5) 16 (45.7) NS
  III 17 (51.5) 18 (51.4) NS
  IV 1 (3.0) 1 (2.9) NS
Arterial blood gas, mean ± SD
  PaO2, kPa 7.42±0.73 7.33±0.69 NS
  PCO2, kPa 8.35±0.41 8.24±0.38 NS
PAP, mmHg, mean ± SD 52.7±8.1 51.7±7.9 NS
Medications
  Oxygen supplementation 33 (100.0) 35 (100.0) NS
  IV or oral glucocorticoids 20 (60.6) 22 (65.7) NS
  Beta2-receptor agonists 28 (84.8) 29 (82.9) NS
  IV frusemide 21 (63.6) 18 (51.4) NS
  Spirolactone 19 (57.6) 20 (57.1) NS
  Digoxin 12 (36.4) 10 (28.5) NS

Data presented as n (%) unless otherwise indicated. IV Intravenous; NS Not statistically significant; NYHA New York Heart Association; PaO2 Arterial oxygen pressure; PAP Pulmonary arterial pressure; PCO2 Arterial carbon dioxide pressure